| Description | STAMBP-IN-1 is a novel selective antagonist of deubiquitinase STAM-binding protein (STAMBP), decreasing NALP7 protein levels and suppressing IL-1β release after TLR agonism. |
| In vitro | 一种小分子抑制剂BC-1471，针对STAMBP去泛素化酶活性，能够降低NALP7蛋白水平并在TLR激动剂作用后抑制IL-1β的释放。这些发现阐述了炎症体调控的独特途径，并将STAMBP作为减少促炎症压力的潜在治疗靶标进行了识别。 |
| molecular weight | 504.6 |
| Molecular formula | C27H28N4O4S |
| CAS | 896683-78-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 5.05 mg/ml (10 mM), Sonication is recommended. H2O: Insoluble |
| References | 1. Joseph S Bednash, Nathaniel Weathington, James Londino.Targeting the deubiquitinase STAMBP inhibits NALP7 inflammasome activity.Nat Commun. 2017 May 11;8:15203. |
| Citations | 1. Guo Y, Liu Q, Mallette E, et al. Structural and functional characterization of ubiquitin variant inhibitors for the JAMM-family deubiquitinases STAMBP and STAMBPL1. Journal of Biological Chemistry. 2021: 101107. |